(CRMD) CorMedix - Ratings and Ratios
Antibiotic, Dialysis, Catheter, Antimicrobial, Lock
CRMD EPS (Earnings per Share)
CRMD Revenue
Description: CRMD CorMedix
CorMedix Inc (NASDAQ:CRMD) is a pharmaceutical company listed on the NASDAQ exchange, operating in the pharmaceuticals industry. To evaluate the companys performance, we need to examine key financial metrics and economic drivers.
The quarterly Income Tax Expense is a crucial aspect of the companys financials, impacting its net income. A thorough analysis of this expense can reveal insights into the companys tax strategy and potential future liabilities. We should consider the effective tax rate, historical tax expenses, and any changes in tax laws or regulations that may affect the company.
To assess CRMDs financial health, we can look at key performance indicators (KPIs) such as revenue growth, gross margin, operating expenses, and cash flow. The companys market capitalization of $974.92M USD and a forward P/E ratio of 9.26 suggest that investors have certain expectations about its future earnings. Return on Equity (RoE) of 0.09 indicates that the company is generating relatively low returns on shareholders equity.
Economic drivers that may impact CRMDs performance include the demand for its pharmaceutical products, competition in the industry, regulatory changes, and overall market trends. The companys beta of 1.710 suggests that its stock price is relatively volatile compared to the broader market. We should also consider the industrys growth prospects, patent expirations, and potential disruptions from new entrants or innovative technologies.
To make informed investment decisions, we need to weigh these factors and consider the companys competitive advantages, managements track record, and its ability to execute on its strategic plans. By analyzing these aspects, we can gain a more comprehensive understanding of CRMDs potential for future growth and returns on investment.
CRMD Stock Overview
| Market Cap in USD | 1,023m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2010-03-25 |
CRMD Stock Ratings
| Growth Rating | 68.9% |
| Fundamental | 70.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 30.1% |
| Analyst Rating | 4.50 of 5 |
CRMD Dividends
Currently no dividends paidCRMD Growth Ratios
| Growth Correlation 3m | 20.7% |
| Growth Correlation 12m | 56% |
| Growth Correlation 5y | 14.6% |
| CAGR 5y | 54.70% |
| CAGR/Max DD 3y | 0.96 |
| CAGR/Mean DD 3y | 2.40 |
| Sharpe Ratio 12m | 0.51 |
| Alpha | 0.19 |
| Beta | 0.108 |
| Volatility | 73.08% |
| Current Volume | 4042.1k |
| Average Volume 20d | 3647.9k |
| Stop Loss | 10.3 (-7.4%) |
| Signal | -1.34 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (51.2m TTM) > 0 and > 6% of Revenue (6% = 7.29m TTM) |
| FCFTA 0.0 (>2.0%) and ΔFCFTA 67.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 178.1k% (prev 3790 %; Δ 174.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 30.5m <= Net Income 51.2m (YES >=105%, WARN >=100%) |
| Current Ratio 7.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (71.9m) change vs 12m ago 24.81% (target <= -2.0% for YES) |
| Gross Margin 95.62% (prev -29.14%; Δ 124.8pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.10% (prev 1.92%; Δ -1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1410 (EBITDA TTM 52.3m / Interest Expense TTM 36.7k) >= 6 (WARN >= 3) |
Altman Z'' -8.06
| (A) 0.86 = (Total Current Assets 248.06b - Total Current Liabilities 31.71b) / Total Assets 252.60b |
| (B) -1.18 = Retained Earnings (Balance) -299.16b / Total Assets 252.60b |
| warn (B) unusual magnitude: -1.18 — check mapping/units |
| (C) 0.00 = EBIT TTM 51.7m / Avg Total Assets 126.33b |
| (D) -9.36 = Book Value of Equity -299.08b / Total Liabilities 31.97b |
| Total Rating: -8.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.85
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 4.94 = -2.50 |
| 6. ROIC - WACC (= 36.97)% = 12.50 |
| 7. RoE 0.09% = 0.01 |
| 8. Rev. Trend 86.79% = 6.51 |
| 9. EPS Trend 76.57% = 3.83 |
What is the price of CRMD shares?
Over the past week, the price has changed by -13.06%, over one month by -15.11%, over three months by -20.23% and over the past year by +54.23%.
Is CorMedix a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRMD is around 11.56 USD . This means that CRMD is currently overvalued and has a potential downside of 3.96%.
Is CRMD a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CRMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.4 | 83.5% |
| Analysts Target Price | 20.4 | 83.5% |
| ValueRay Target Price | 12.5 | 12.4% |
Last update: 2025-09-05 04:38
CRMD Fundamental Data Overview
CCE Cash And Equivalents = 190.71b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 17.5641
P/E Forward = 6.6094
P/S = 8.4183
P/B = 4.6302
Beta = 1.71
Revenue TTM = 121.5m USD
EBIT TTM = 51.7m USD
EBITDA TTM = 52.3m USD
Long Term Debt = 258.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 354.3k USD (from shortTermDebt, last quarter)
Debt = 258.4m USD (Calculated: Short Term 354.3k + Long Term 258.1m)
Net Debt = -158.87b USD (from netDebt column, last quarter)
Enterprise Value = -189.43b USD (1.02b + Debt 258.4m - CCE 190.71b)
Interest Coverage Ratio = 1410 (Ebit TTM 51.7m / Interest Expense TTM 36.7k)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value -189.43b)
FCF Margin = unknown (0.0 / 121484498.0)
Net Margin = 42.11% (Net Income TTM 51.2m / Revenue TTM 121.5m)
Gross Margin = 95.62% ((Revenue TTM 121.5m - Cost of Revenue TTM 5.32m) / Revenue TTM)
Tobins Q-Ratio = 0.63 (Enterprise Value -189.43b / Book Value Of Equity -299.08b)
Interest Expense / Debt = 0.00% (Interest Expense 6671 / Debt 258.4m)
Taxrate = 2.56% (521.5k / 20.3m)
NOPAT = 50.4m (EBIT 51.7m * (1 - 2.56%))
Current Ratio = 7.82 (Total Current Assets 248.06b / Total Current Liabilities 31.71b)
Debt / Equity = 0.00 (Debt 258.4m / last Quarter total Stockholder Equity 220.63b)
Debt / EBITDA = 4.94 (Net Debt -158.87b / EBITDA 52.3m)
Debt / FCF = none (Debt 258.4m / FCF TTM 0.0)
Total Stockholder Equity = 55.22b (last 4 quarters mean)
RoA = 0.02% (Net Income 51.2m, Total Assets 252.60b )
RoE = 0.09% (Net Income TTM 51.2m / Total Stockholder Equity 55.22b)
RoCE = 0.09% (Ebit 51.7m / (Equity 55.22b + L.T.Debt 258.1m))
RoIC = 42.09% (NOPAT 50.4m / Invested Capital 119.7m)
WACC = 5.12% (E(1.02b)/V(1.28b) * Re(6.41%)) + (D(258.4m)/V(1.28b) * Rd(0.00%) * (1-Tc(0.03)))
Shares Correlation 3-Years: 100.00 | Cagr: 5.20%
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
EPS Correlation: 76.57 | EPS CAGR: 78.63% | SUE: 2.70 | # QB: 4
Revenue Correlation: 86.79 | Revenue CAGR: 2241 % | SUE: 3.26 | # QB: 2
Additional Sources for CRMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle